AEMD: Aethlon Medical, Inc. Stock

by  •  • Comments Off on AEMD: Aethlon Medical, Inc. Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 7.12
Enterprise Value ($M) 2.29
Book Value ($M) 4.33
Book Value / Share 0.21
Price / Book 1.64
NCAV ($M) 2.78
NCAV / Share 0.13
Price / NCAV 2.56

Profitability (mra)
Return on Invested Capital (ROIC) -1.89
Return on Assets (ROA) -1.16
Return on Equity (ROE) -1.66

Liquidity (mrq)
Quick Ratio 2.80
Current Ratio 2.80

Balance Sheet (mrq) ($M)
Current Assets 4.97
Assets 6.53
Liabilities 2.19
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Ikarian Capital, LLC 8.70

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPOR
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-15 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 ☐ TRANSIT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-06-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-09 8,613 51,024 16.88
2025-05-08 52,899 138,333 38.24
2025-05-07 3,086 41,754 7.39
2025-05-06 36,750 72,403 50.76
2025-05-05 5,142 21,629 23.77

(click for more detail)

Similar Companies
AMIX – Autonomix Medical, Inc. AXGN – Axogen, Inc.


Financial data and stock pages provided by
Fintel.io